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ABSTRACT
Use of botanicals for self-diagnosed conditions or recreational purposes is increasing.
Many readily available botanicals are under-researched and little is known about potential
liabilities. This study sought to utilize Conditioned Place Preference (CPP) to quantify rewarding
or aversive properties of botanicals and their constituents in rats. This paradigm is based on the
notion that animals prefer distinct environments previously paired with rewarding drugs. Our
approach to broadly characterize a botanical and its many constituents entails dose response
functions of a plant extract, its fractions, and its primary constituent. As a proof of concept, we
chose two popular botanicals, one expected to produce place preference (Mitragyna speciosa)
and the other expected to produce place aversion (Salvia divinorum). Because salvinorin A is
well characterized as the major psychoactive compound, we did not study an extract fraction for
S. divinorum. Following apparatus habituation and quantification of baseline compartment
preference, male Sprague-Dawley rats were given eight drug-compartment conditioning trials
which involved alternate day pairings of test compound to one compartment and vehicle to the
other. This was followed by a compartment preference trial conducted under drug-free states. As
expected, rats showed place preference to mitragynine similar to that of 1mg/kg (+)Amphetamine. This effect was much less pronounced with the extract and its fractions. Rats
showed robust place aversion to both Salvia divinorum and salvinorin A. These findings suggest
that products that contain significant quantities of mitragynine pose an abuse liability.
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INTRODUCTION
Botanicals are entering the consumer market at a rapid pace and are widely available to
consumers in a variety of forms. These products are often purchased by consumers to treat
medical disturbances as well as for recreational purposes (Dennehy, Tsourounis, & Miller,
2005). In many cases, these plants are on the market with little knowledge of their range of
action, toxicity, and abuse potential. However, consumers are comforted by the “all natural”
label and continue to use the products because they falsely believe that this label indicates safety
and a lack of physical and psychological health risks (Marcus & Grollman, 2002). Botanicals can
be dangerously complex due to their wide arrays of constituents. While one effect of a botanical
may be understood, numerous other constituents present in the same plant may lead to harmful
effects. Even if the activity of the primary active constituent is understood, this knowledge may
not be enough to have a full understanding of the plant’s potential toxicity risks. Wide
availability of under-researched botanical compounds could easily lead to a plethora of
physiological and psychological disturbances in an unsuspecting group of consumers.
Kava-kava is an example of a botanical that found its way into the consumer market and
led to severe toxicity in some users. The compound is extracted from the roots of Piper
mesthysticum, a kava plant native to the South Pacific Oceanic Islands. Islanders traditionally
consumed the drink for its intoxicating effects. Expansive knowledge on traditional use led to no
worrisome side effects or glaring health risks (Whitton et al., 2003).
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Kava-kava gained popularity in the West and modern consumers used it to aid in sleep,
reduce anxiety, and as an alternative intoxicant to alcohol (Whitton et al., 2003). The Drug
Enforcement Administration’s Office of Diversion Control states on its Drug and Chemicals of
Concern list that kava is sold as a dietary supplement and serves as a natural alternative to antianxiety medications. They also state that, while research on illicit use of kava is purely
anecdotal, consumers are utilizing the plant for relaxation and its mild euphoric states. In
addition, it is often used as a sleep aid ("Drugs and Chemicals of Concern: Kava").
The increased popularity of kava-kava was not without adverse consequences.
Hepatotoxicity has been reported in a number of individuals regularly using kava (Humberston,
Akhtar, & Krenzelok, 2003; Teschke, Schwarzenboeck, & Akinci, 2008). More specifically,
liver damage, including hepatitis and cirrhosis, and full liver failure have been linked to kava use
("Drugs and Chemicals of Concern: Kava").
Observations of toxicity associated with kava-kava are not surprising given current
analysis of this product. In an in vitro model of liver toxicity, kava extracts were found to cause
toxic effects (Lüde et al., 2008). Further, kavalactones were shown to disrupt liver detoxification
pathways due to inhibition of cytochrome P450 activity in addition to reducing the natural levels
of glutathione in the liver (Clouatre, 2004).
Present-day consumers are engaged in self-diagnosing and using wholly unregulated
botanicals for the treatment of a variety of maladies. They are being prescribed and selfprescribing unstandardized botanicals without any empirical evidence for efficacy or any
empirical knowledge of potential toxicity. Further, no systematic studies have evaluated proper
dosing and possible drug-drug interactions in many of these compounds. These issues alone
would justify the need of a scientific approach for systematically studying these botanicals.
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The recreational use of botanicals marketed to produce pleasurable psychoactive effects
is another major concern. These botanicals are widely available at local “head shops” and
through online botanical pharmacies (Dennehy, Tsourounis, & Miller, 2005). One attraction to
the use of understudied botanicals as recreational compounds is that they are unregulated. As
with botanicals used medicinally, recreational botanicals have not been properly evaluated for
abuse liability or for toxicity associated with the product.
Animal models are often used to evaluate properties of drug substances. A common
animal model used to identify abuse potential is the Conditioned Place Preference paradigm
(CPP). CPP is based on the notion that animals prefer environments previously paired with
positively reinforcing drugs (Bardo & Bevins, 2000). The paradigm has three phases: 1)
habituation and initial compartment preference, 2) conditioning through pairing drug/no-drug
treatments in chambers with distinct stimuli, and 3) testing the conditioned animal under drugfree states. Preference is determined by animals spending significantly more time in the drugpaired chamber and aversion is determined by animals spending significantly less time in the
drug-paired chamber.
Because botanical products typically contain a large array of constituents, determining
abuse potential is more challenging. This is due to the possibility of the plant containing more
than one psychoactive constituent with rewarding or antagonistic effects. For example, a
botanical may have a primary active constituent with abuse potential, but in combination with
antagonistic constituents present, it will not indicate preference. Thus, studying entire plants for
abuse potential could lead to false negatives in this paradigm. On the other hand, studying
individual constituents could also lead to false negatives. This could occur if preference relies on
the synergistic effects of multiple constituents.
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A solution to the previously outlined problem is a methodical approach in which the
whole plant extract, a fraction of the extract, and the plant’s believed active constituent are
evaluated. With this approach, the paradigm can identify a) if the believed active constituent is
wholly responsible for a plant’s psychoactive effects, b) if there are further rewarding or aversive
qualities in other constituents, and c) if the constituents responsible for alternative qualities are
present in the selected fraction. The process of identifying other psychoactive constituents can be
narrowed down by evaluating whether the fraction shows the same qualities of the whole plant
extract. If so, the fraction will be known to contain the responsible constituent. If not, further
evaluation of constituents present in the whole plant extract will be necessary. In either case, it
will be highlighted that there are additional psychoactive properties in the plant.
As a proof of concept, two products were evaluated using this method: one expected to
produce place preference and another expected to produce place aversion. These expectations
were developed based on human responses to recreational or medicinal use, broad historical
backgrounds and traditional uses, and an understanding of receptor binding activity in the two
plants. Of the many available, we selected Salvia divinorum (S. divinorum) to serve as the
aversive botanical and Mitragyna speciosa (M. speciosa) to serve as the rewarding botanical.
S. divinorum, a member of the Sage family and native to Mexico, is also known as
“Diviner’s Sage,” “Mystic Sage,” and “Magic Mint” (Babu, McCurdy, & Boyer, 2008). S.
divinorum was traditionally consumed by means of water infusion (Valdéz III, Díaz, & Paul,
1983). The Drug Enforcement Administration has listed S. divinorum and its active constituent,
salvinorin A, on the drug or chemical of concern list. Several states have already placed
regulatory control on both S. divinorum and salvinorin A ("Drugs and Chemicals of Concern:
Salvia Divinorum,"). Traditionally, the Mazatec tribe of Oaxaca, Mexico used S. divinorum for
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both the divination of shamans through hallucinations as well as for curing a variety of
physiological and psychological ailments in community members (Valdéz III et al., 1983). In the
1960s, nearly all Mazatec tribe members claimed to be aware of the botanical (Wasson, 1962).
Today, S. divinorum is in the spotlight because it is marketed as a legal hallucinogen and
is readily available to consumers (Griffin, Miller, & Khey, 2008; Hillebrand, Olszewski, &
Sedefov, 2010). Use of the botanical is growing rapidly in the young adult population with 5.9%
of high schools seniors reporting to have used S. divinorum in the last year ("Drugs and
Chemicals of Concern: Salvia Divinorum,"). In states without restrictions, S. divinorum can be
purchased at “head shops.” In addition, it is one of the most widely available herbal dietary
supplements suggested for recreational use on the internet (Dennehy et al., 2005). Consumers are
now using the plant by means of smoking the leaves or smoking pure salvinorin A ("Drugs and
Chemicals of Concern: Salvia Divinorum,").
Salvinorin A is the known active alkaloid and other constituents in the plant are not
believed to have psychoactive properties ("Drugs and Chemicals of Concern: Salvia
Divinorum,"). Receptor binding studies have demonstrated that salvinorin A acts as a κ-opioid
receptor agonist (Chavkin et al., 2004). Previous studies have shown that κ-agonists act as a
psychotomimetic in humans and, not surprisingly, cause place aversion in rodent models (Mucha
& Herz, 1985; Pfeiffer et al., 1986). Consistent with these findings, salvinorin A has been shown
to produce place aversion in mice (Zhang et al., 2005).
M. speciosa, a member of the Rubiaceae family and native to Southeastern Asia, is
widely known as “Kratom,” but is also called “Biak-biak” and “Ketum” in Malaysia (Ahmad &
Aziz, 2012). Consumption of the plant is primarily achieved through chewing fresh leaves but
some users grind and swallow leaves or use the leaves in a tea (Assanangkornchai et al., 2007).
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The Drug Enforcement Administration has listed mitragynine as the primary active alkaloid in
M. speciosa. The plant has long been a part of southern Thailand history and traditions with its
use first recorded in 1935. The botanical was medicinally used for pain, infection, coughing, and
diarrhea (for review: Hassan et al., 2013).
A recent survey in northern Thailand revealed that most local M. speciosa users were
consuming the plant to increase physical endurance for long, physically demanding work days
(Ahmad & Aziz, 2012). Currently, western consumers have begun to purchase the botanical for
its stimulant like effects at low doses and its opiate-like and sedative effects at higher doses
("Drugs and Chemicals of Concern: Mitragyna speciosa,"). These recreational uses of the plant
are not isolated to the West; use amongst young people in Thailand is increasing due to the
introduction of a homemade cocktail called 4x100. The cocktail includes boiled M. speciosa
leaves, cough syrup, and Coca-Cola (Tanguay, 2011).
Mitragynine is the major active chemical constituent found in M. speciosa and is not
found in any other Mitragyna plants (Shellard, 1974). Mitragynine has been shown to have high
affinity to the µ-opioid receptor (Watanabe et al., 1997; Yamamoto et al., 1999). Previous studies
have shown that µ-opioid receptor agonists play a role in addiction (for review Koob, Sanna, &
Bloom, 1998). A study looking at current users revealed that 88% of daily users were unable to
stop using the plant (Ahmad & Aziz, 2012). Not surprisingly, µ-opioid receptor agonists have
been shown to produce place preference in a rodent model (Bardo, Rowlett, & Harris, 1995).
In the present project, rewarding and aversive properties of S. divinorum and M. speciosa
will be characterized using the CPP model. The full plant extract and the major psychoactive
constituent will be evaluated in both plants in addition to a fraction of the constituents in M.
speciosa. Salvinorin A’s CNS action and behavioral effects are well understood, but there is a
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chance that other minor constituents possess antagonistic or synergistic effects. In testing the
whole plant extract, the presence of any unknown psychoactive components or potential
synergistic effects will be realized. Thus, to reduce animal use, a fraction of S. divinorum will not
be evaluated.
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METHODS

Male Sprague Dawley rats (175-200 g, 6-7 weeks old; Harlan, Indianapolis, IN) served as
subjects for these experiments. Animals were housed in pairs and maintained under a 12-h
light/dark cycle in a temperature and humidity controlled vivarium. Food and water were
available ad libitum. Animals had a 3-day period in which they were not tested but handled by
experimenters to acclimate to the vivarium and to reduce experimenter-related stress. In both
experiments, conditions had a sample size of 7-10.
Five place preference chambers (Model MED CPP RS; Med Associates, St. Albans, VT)
were used for the experiment. Each chamber has three compartments: two stimulus-distinct,
drug-conditioning chambers and a centralized “neutral” start chamber. Guillotine doors provide
access between the start chamber and the conditioning chambers. Each conditioning chamber
measures 30 x 30 x 30 cm. The stimuli of the two conditioning compartments are distinct on the
basis of visual and tactile cues. One compartment is white with wire mesh floor and the other
compartment is black with a metal rod floor. The center chamber measures 15 x 30 x 30 cm and
is gray with a solid floor.
The Conditioned Place Preference procedure (Bardo & Bevins, 2000) involves four
phases: 1) a 15 minute apparatus habituation trial under drug free states, 2) a 15 minute baseline
preference trial under drug free states, 3) eight 30 minute drug/drug-free conditioning trials, and
4) a final 15 minute place preference trial under drug-free states. Animals had access to the entire
place preference apparatus during the habituation, baseline, and final preference trials. Baseline
8

preference trials were used to identify any initial compartment bias to aid in assigning
compound pairing conditions. The conditioning phase was characterized by alternate day
pairings of test compound in one compartment (S+ compartment) and vehicle in the other (Scompartment). S+ was determined by selecting the non-preferred side if the compound was
expected to produce CPP and the preferred side for compounds expected to produce CPA. Test
apparatus was thoroughly cleaned after each trial. Compound or vehicle was administered via
intraperitoneal (IP) injection immediately preceding each conditioning trial. Conditioning trials
were counter-balanced for order (drug/vehicle) within treatments conditions. Compartment and
compound/vehicle assignments were also counter-balanced and assigned based on initial
preference scores. Following the final phase of the procedure, the change in time spent in the S+
compartment pre- and post-conditioning was analyzed.

Drug Probes
Experiment I
Morphine has previously been used as a compound to establish preference seeking
behavior in this paradigm (for review: Tzschentke, 2007). In this experiment, 10 mg/kg of
Morphine served as a “positive” control for quantifying conditioned place preference (CPP).
Haloperidol, on the other hand, has previously been used as a compound to establish aversion in
this paradigm (for review: Tzschetke, 1998). 1 mg/kg of Haloperidol served as the “negative”
control for quantifying conditioned place aversion (CPA). Morphine was diluted in physiological
saline. 50% DMSO and 50% saline were used as the vehicle for haloperidol (1.0 ml/kg).
Salvia divinorum extract (10, 30, 100 mg/kg) was prepared by exhaustive extraction of
dry plant material with ethanol. The extract was filtered and then concentrated. Because it is
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well-established that the psychoactive properties of S. divinorum are mediated by salvinorin A,
we opted to not include analysis of a S. divinorum fraction. Salvinorin A (0.1, 0.3, 1.0 mg/kg)
was isolated from S. divinorum leaves as previously described (Munro & Rizzacasa, 2003).
Briefly, S. divinorum leaves were extracted with acetone and subsequently recrystallized from
95% ethanol to yield 99% (HPLC) pure salvinorin A. The salvinorin A doses selected were
based on previously published studies in rodent models (McCurdy et al, 2006) and, for S.
divinorum, dosing equivalence based on concentrations of salvinorin A in the extract. 10%
DMSO and 10% Tween80 were used as the vehicle for S. divinorum and salvinorin A (1.0
ml/kg).

Experiment II
In the second experiment, d-amphetamine (1 mg/kg), instead of morphine, served as the
“positive” control. D-amphetamine has previously been used to establish preference seeking
behavior in this paradigm (for review: Tzschetke, 1998). This was used because it was
anticipated that M. speciosa may show some psychostimulant properties. Haloperidol (0.8
mg/kg) served as the “negative” control. Amphetamine was diluted in physiological saline. 50%
DMSO and 50% saline were used as the vehicle for haloperidol (1.0 ml/kg).
The leaves of M. speciosa (Voucher # 12433) were exhaustively extracted with methanol
and the solvent was removed under reduced pressure to yield a dried extract. An aliquot was
suspended in 5% HCl in water and extracted with ethyl acetate. The water-soluble part was
basified (pH 9-10) with liquid ammonia and extracted with ethyl acetate. The ethyl acetatesoluble part, separated from basic media, was dried under reduced pressure to get an alkaloid
enrich fraction. Mitragynine (97% pure) was isolated from the alkaloid enrich fraction by
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repeated column chromatogaraphy over silica gel using chloroform/methanol (9:1) and
hexanes/acetone/liq. ammonia (210:90:1) solvent systems. From these processes, M. speciosa
extract (750, 1500, 4500 mg/kg), alkaloid enrich fraction (187.5, 375, 1125 mg/kg) and
mitragynine (75, 150, and 450 mg/kg) were used in this study. The mitragynine doses selected
were based on previously published studies in rodent models (Sabetghadam et al, 2013) and for
M. speciosa, the dosing equivalence based on concentrations of mitragynine in the extract. In
this study, S(+)-amphetamine (1 mg/kg in saline) served as the positive control for CPP and
haloperidol (0.8 mg/kg) served as the negative control for CPA. Two vehicles were used and
tested in this study. 20% Tween80 and saline were used as the vehicle for M. speciosa, the
fraction, and mitragynine.

Data Acquistion and Analyses
All data acquisition was handled by infrared photo-beam detection via MED-PC® IV and
analyses were conducted using SPSS statistical software. Group differences (preference/aversion
scores) were analyzed using one-way ANOVAs. Preference scores are defined as (time spent in
S+ post-conditioning – time spend in S+ pre-conditioning). A small change in relative time
between S+ and S- chambers is expected in the vehicle groups simply due to repeated exposures.
Relevant post hoc analyses will be performed using Fisher’s LSD. Rewarding or aversive
properties of compounds were determined by a statistically significant (p < 0.05) increase or
decrease in preference scores relative to vehicle treated rats.
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RESULTS
Experiment 1
To reduce the number of animals used, 5 vehicle animals received the haloperidol vehicle
and 5 received the S. divinorum vehicle. A one-way ANOVA comparing preference scores was
conducted and revealed no significant differences between these two groups. Therefore, vehicle
groups were combined prior to computation of the analyses detailed below.
Preference scores for Experiment I are summarized in Figure 1. As expected, vehicle
group preference scores changed minimally, increasing only +23 seconds. This minor change
score is now depicted as the x-axis in Figure 1. Morphine treated animals tended to have higher
preference scores and haloperidol treated animals tended to have lower preference scores
compared to vehicle treated groups. In general, both S. divinorum and salvinorin A show a
pattern of place aversion across all doses tested. To illustrate the place preference/aversion
effects across treatment groups, a one-way ANOVA was performed on these data and revealed a
significant main effect for treatment condition, F(8,73) = 3.986, p = 0.001. Post-hoc analyses
revealed that mean preference scores for the morphine (positive control) condition did not
significantly differ from the vehicle. The mean preference score for haloperidol was not, but
approached being, significantly lower than the vehicle group, (p = 0.083). Mean preference
scores for 10 and 100 mg/kg S. divinorum were statistically significantly lower than the vehicle,
(p = 0.022 and p < 0.001). The 30 mg/kg S. divinorum extract condition was not, but approached
being, significantly lower than the vehicle group, (p = 0.073). The mean preference scores of the
0.3 and 1.0 mg/kg salvinorin A groups were statistically significantly lower than the vehicle
12

group, (p = 0.004 and p = 0.004). The mean preference score of the 0.1 mg/kg salvinorin
A group was in the direction of being significantly lower than the vehicle, (p = 0.051).

Experiment 2
To reduce the number of animals used, 5 vehicle animals received the haloperidol vehicle
and 5 received the M. speciosa vehicle. A one-way ANOVA comparing preference scores was
conducted and revealed no significant differences between these two groups. Therefore, vehicle
groups were combined prior to computation of the analyses detailed below.
Preference scores for Experiment II are summarized in Figure 2. As expected, vehicle
group preference scores changed minimally, increasing approximately +30 seconds. This minor
change score is now depicted as the x-axis in Figure 2. D-Amphetamine treated animals have
higher preference scores and haloperidol treated animals tended to have lower preference scores.
In general, the M. speciosa extract, its fraction, and its active, mitragynine, show a pattern of
place preference across nearly all doses. To illustrate the place preference/aversion effects across
treatment groups, a one-way ANOVA was performed on these data and revealed a significant
main effect for treatment condition, F(11,101) = 2.97, p = 0.002. Post-hoc analyses revealed that
the mean preference score for d-Amphetamine (positive control) condition significantly differed
from the vehicle group, (p = 0.016). The mean preference score of haloperidol was in the
direction of being significantly lower than the vehicle, (p = 0.09). Mean preference scores for 75
and 450 mg/kg mitragynine groups were significantly higher than the vehicle, (p = 0.027 and p =
0.026). Mean preference score for 150 mg/kg mitragynine group was not, but approached being,
significantly higher than the vehicle group, (p = 0.076).
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DISCUSSION
Experiment 1
The goal of the first experiment was to characterize rewarding or aversive properties of S.
divinorum and salvinorin A. Following apparatus habituation and quantification of baseline
compartment preference, male Sprague-Dawley rats were given eight drug-compartment
conditioning trials, which involved alternate day pairings of test compound to one compartment
(S+) and vehicle to the other (S-). This was followed by a compartment preference trial
conducted under drug-free states. Preference was defined by animals spending significantly more
time in the drug conditioned chamber after conditioning.
Vehicle animals spent approximately the same amount of time in the S+ chamber before
and after conditioning. This indicates that animals do not show compartment bias to the
apparatus after repeated conditioning trials. Surprisingly, morphine, our positive control, failed
to show place preference. However, the literature on morphine place preference is equivocal.
Some labs report place preference across a range of doses whereas others do not (i.e. 1 – 10
mg/kg). Two factors may have played a role in this finding. First, the dose may have been too
high (10 mg/kg) as this appears to produce more mixed results than lower doses (for review:
Tzschentke, 2007). Secondly, the loss of three data points certainly compromised statistical
power. In this study, 1 mg/kg haloperidol produced modest place aversion. The lack of
significance was potentially due to too high a dose. The earliest study showing CPA with
haloperidol used a much lower dose of 0.1 mg/kg in mice (Risinger, Dickinson & Cunningham,
1992). Thus, haloperidol dosing was lowered to 0.8 mg/kg for the second experiment.
14

Salvinorin A showed a pattern of place aversion across all doses. This is not surprising as
previous research shows salvinorin A producing place aversion (Zhang, Butelman, Schlussman,
Ho, & Kreek, 2005). Salvinorin A is a κ-opioid receptor agonist and κ-agonists are known to
produce robust place aversion in the CPP paradigm (Mucha & Herz, 1985). S. divinorum also
produced place aversion approximate to that of salvinorin A. This is not surprising as salvinorin
A is the major constituent in S. divinorum ("Drugs and Chemicals of Concern: Salvia
Divinorum,"). These observations suggest that salvinorin A is also the main constituent
responsible for the place aversion observed with administration of S. divinorum. In previous
research, compounds that produce CPA lack abuse potential (Sufka, 1994). Collectively, these
findings indicate that both S. divinorum and salvinorin A lack abuse potential.

Experiment 2
The goal of the second experiment was to characterize rewarding or aversive properties
of M. speciosa, a fraction of the botanical, and its active, mitragynine. Following apparatus
habituation and quantification of baseline compartment preference, male Sprague-Dawley rats
were given eight drug-compartment conditioning trials which involved alternate day pairings of
test compound to one compartment and vehicle to the other. This was followed by a
compartment preference trial conducted under drug-free states. Preference was defined by
animals spending significantly more time in the drug conditioned chamber after conditioning.
Vehicle animals spent approximately the same amount of time in the S+ chamber before
and after conditioning. This indicates that animals do not show compartment bias to the
apparatus after repeated conditioning trials. Consistent with the literature, d-amphetmine, our
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positive control, produced robust place preference (for review see: (Tzschentke, 2007)). Using a
slightly lower dose of haloperidol, our negative control, produced marginal place aversion.
Mitragynine shows place preference across doses with robust effects seen at the low and
high doses, indicative of abuse potential. This is not surprising, as previous research shows that
mitragynine displays affinity to µ-opioid receptors. Compounds with affinity to µ-opioid
receptors are known to produce robust place preference (for review see: Hassan et al., 2012).
These findings are also consistent with anecdotal evidence suggesting that consumers have
difficulty stopping use of the plant (Ahmad & Aziz, 2012).
The whole plant extract of M. speciosa shows a pattern of place preference but does not
reach significance at any of the doses. The fraction of the plant, however, shows far less
rewarding activity than the whole plant extract and mitragynine. In the doses of both the extract
and the fraction, the amount of mitragynine mirrors the doses used when testing the active
constituent alone. With the amount of mitragynine steady, appearance of significant CPP in
mitragynine alone but not in the extract or fraction raises questions. It is suspected that there may
be a constituent present in both the whole plant extract and the fraction that is either 1) producing
place aversion thus mediating the preference caused by mitragynine or 2) antagonizing the
activity of mitragynine.

Future studies
Botanicals typically contain a large variety of constituents that may possess a diverse
array of activity. Because of this complexity, the study of botanicals can lead to false negatives
when lacking methods that allow for a broad analysis of the plant’s psychoactive properties. An
example of this problem can be observed in the current evaluation of M. speciosa, where results
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were not consistent across the whole plant extract, fraction, and mitragynine. The current study
utilized a novel approach in which three doses of the entire plant extract, a fraction of the active
constituents, and the plant’s primary active constituent were tested. This approach allows for a
more complete evaluation of the large array of constituents comprising a botanical. Researchers
can identify a) if the believed active constituent is wholly responsible for a plant’s psychoactive
effects, b) if there are further rewarding or aversive qualities in other constituents, and c) if the
constituents responsible for alternative qualities are present in the selected fraction. Researchers
may want to adopt this 3-tiered approach in future research evaluating botanical products that are
suspect for abuse liability and other psychoactive qualities.
Given the varying results of M. speciosa, its fraction, and mitragynine, further evaluation
of the plant’s constituents would make an interesting follow up study. The current findings
support evidence of other active constituents with aversive qualities or constituents synergistic to
mitragynine. Paynantheine and Speciogynine make up 9 and 7% of the plant, respectively, and
may be valuable to investigate. In addition, 7-hydroxymitragynine has been identified as a minor
constituent, comprising 2% of the plant, and may be a good option to study (for review see:
(Hassan et al., 2013)). Research evaluating alternate constituents of M. speciosa, such as 7hydroxymitragynine, would help researchers to gain a broader understanding of psychoactive
qualities of the botanical. If there is a constituent that is not aversive and synergistically interacts
with mitragynine’s rewarding effects to reduce CPA, this could open new doors in the study of
addiction. This constituent could offer insight in attenuating addictive qualities in other drugs of
abuse.
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FIGURE CAPTIONS
Figure 1. The effects of S. divinorum and salvinorin A on place preference. Values represent
mean change in seconds (±SEM) spent in S+ chamber before and after drug-conditioning during
a 15 min drug-free test. Solid horizontal line reflects the mean preference score for the vehicle
group and is provided for comparative purposes. Scores above baseline signify place preference
while scores below baseline signify place aversion. * indicates a significant difference from the
vehicle group. Sample sizes were 7-10.

Figure 2. The effects of M. speciosa, its fraction, and mitragynine on place preference. Values
represent mean change in seconds (±SEM) spent in S+ chamber before and after drugconditioning during a 15 min drug-free test. Solid horizontal line reflects the mean preference
score for the vehicle group and is provided for comparative purposes. Significant conditions that
are higher than the baseline signify preference while significant conditions that drop lower than
the baseline signify aversion. . * indicates a significant difference from the vehicle group.
Sample sizes were 9-10.

25

APPENDIX B

26

FIGURES

Figure 1

Figure 2

27

VITA

MELISSA LORIA
458A Highway 334

•

Oxford, MS 38655

EDUCATION
August 2011—present

September 2007—August 2010

• (662) 816-5720

•

mjloria@olemiss.edu

Doctor of Philosophy in Clinical Psychology, Anticipated
May 2016, University of Mississippi, Oxford, MS
Bachelor of Arts in Psychology, University of Mississippi

PUBLICATIONS and PRESENTATIONS
Hymel KA, Loria MJ, White SW, Salmeto AL, Sufka KJ (June 2013). Strain Vulnerability and
Resiliency in the chick anxiety-depression model. 42nd Annual Meeting of the Society
for Neuroscience, New Orleans, LA.
Lewellyn KD, Bialonska ND, Chaurasiya BL, Tekwani, BL, Loria, MJ, White SW, Sufka KJ,
Zjawiony JK (2012). In vitro and in vivo evaluation of the antidepressant activity of
aplysinopsin analogs. Planta Medica.
Loria MJ, Harris HM, Lewellyn K, Zjawiony JK, Ali Z, Khan IA, Sufka KJ (April 2013).
Evaluating Preference-Seeking and Aversive Qualities of Salvia Divinorum and
Mitragyna Speciosa. 12th Annual Oxford International Conference on the Science of
Botanicals. University of Mississippi.
Loria MJ, White SW, Robbins SA, Salmeto AL, Hymel KA, Murthy SN, Manda P, Sufka KJ
(2013) Brain-derived neurotrophic factor in vulnerable and resilient genetic lines in the
chick anxiety-depression model. Behavioral Brain Research.
Loria MJ, White SW, Robbins SA, Salmeto AL, Hymel KA, Murthy SN, Manda P, Sufka KJ
(2013) Brain-derived neurotrophic factor in vulnerable and resilient genetic lines in the
chick anxiety-depression model. 42nd Annual Meeting of the Society for Neuroscience,
New Orleans, LA.
Loria MJ, White SW, Robbins SA, Salmeto AL, Hymel KA, Murthy SN, Manda P, Sufka KJ
(2013) Brain-derived neurotrophic factor in vulnerable and resilient genetic lines in the
28

chick anxiety-depression model. 20th Annual International "Stress and Behavior"
Neuroscience and Biopsychiatry Conference, New Orleans, LA.

Salmeto AL, Hymel KA, Loria MJ, White SW, Sufka KJ (June 2013). Strain Vulnerability and
Resiliency in the chick anxiety-depression model. 20th Annual International "Stress and
Behavior" Neuroscience and Biopsychiatry Conference, New Orleans, LA.

29

